Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | BCR | P11274 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP8B1 | Q9UNU6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21050820 | 0.92 | MAPT (0.37) | MAPTABL1BCRGAASMN1; SMN2 | |
| SCHEMBL21050673 | 0.83 | ABL1 (0.38) | MAPTABL1BCRGAASMN1; SMN2 | |
| SCHEMBL21099342 | 0.81 | MET (0.38) | MAPTCYP8B1 | |
| SCHEMBL21050906 | 0.81 | MAPT (0.37) | MAPTABL1BCRGAASMN1; SMN2 | |
| SCHEMBL21050943 | 0.80 | MAPT (0.36) | MAPTABL1BCRGAASMN1; SMN2 | |
| SCHEMBL21050774 | 0.79 | MAPT (0.38) | MAPTABL1BCRGAASMN1; SMN2 | |
| SCHEMBL21050809 | 0.77 | CYP8B1 (0.33) | ABL1BCRCYP8B1 | |
| SCHEMBL21052504 | 0.74 | ABL1 (0.35) | MAPTABL1BCRSMN1; SMN2CYP8B1 | |
| SCHEMBL28974699 | 0.72 | SMN1; SMN2 (0.41) | MAPTGAASMN1; SMN2 | |
| SCHEMBL27242751 | 0.72 | SMN1; SMN2 (0.41) | MAPTGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597405-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2020-03-24 | — | — | US | disclosed |
| US-20190177338-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177338-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | MAPT 2445/4885ABL1 84/4885BCR 1121/4885 |
| US-10597405-B2 | Chemical compounds | MKI67, CCNI, MCL1 | MAPT 2445/4885ABL1 84/4885BCR 1121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.